Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT

Reuters

Jan 30

Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT

Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine $(NCT)$ using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131921) on January 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607063684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607063684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607063684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 08:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607063684","market":"fut","top_or_hot":-1,"title":"Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine <a href=\"https://laohu8.com/S/NCT\">$(NCT)$</a> using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131921) on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine <a href=\"https://laohu8.com/S/NCT\">$(NCT)$</a> using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131921) on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXOZ","symbol_name":"eXoZymes Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL4qTvP6:1","article_id":"2607063684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607063684","pubTimestamp":1769733913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine  using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXOZ":"eXoZymes Inc","BK4139":"生物科技"},"translate_title":"Exozymes Inc.实现高纯度NCT中试生产突破性进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXOZ":0.9},"content_text":"Exozymes Inc. Achieves Breakthrough Pilot-Scale Production of High-Purity NCT\n    \n\n        Exozymes Inc. has announced detailed results from a 100-liter pilot production run of N-trans-caffeoyltyramine $(NCT)$ using its AI-enhanced enzymes, known as exozymes. The pilot, executed by Cayman Chemical as an independent external partner, demonstrated improved reaction performance at larger scales, achieving approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity. These findings support the scalability and robustness of Exozymes' biomanufacturing process, with high-purity NCT now available for formulation development with commercial partners. The results have already been reported by the company.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131921) on January 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}